Palisade Bio is a clinical stage biopharmaceutical company dedicated to advancing next-generation precision therapies for immune, inflammatory and fibrotic diseases. These conditions represent a significant unmet need, leading to chronic organ dysfunction, damage and even failure due to abnormal immune responses and persistent inflammation.

Palisade Bio’s lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug in development for the treatment of moderate-to-severe ulcerative colitis. Ulcerative colitis represents a significant challenge for patients, who are in need of therapies that provide effective remission rates, are non-immunosuppressive and have improved safety.

Using advanced machine learning, they aim to identify patients with elevated PDE4 activity to enhance the responder population in our lead program targeting ulcerative colitis. By pinpointing key markers of colitis through RNA sequencing and meta-analysis, Palisade Bio identifies top PDE4-effector genes, enabling them to predict potential patient responses to PDE4 inhibitors and potentially ensure targeted, effective treatment.

Palisade Bio’s platform technology provides the opportunity to grow their pipeline across immune, inflammatory and fibrotic disease, including our program, PALI-1908, that is in preclinical development for fibro stenotic Crohn’s Disease, and which has multiple synergies with their lead PALI-2108 program.